secwatch.observer — SEC 8-K summary
======================================

Issuer:     Tyra Biosciences, Inc. (TYRA)
CIK:        0001863127
Form:       8-K
Filed at:   2022-11-03T23:59:59+00:00
Accession:  0000950170-22-021888
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Tyra Biosciences Q3 net loss widens to $12.5M; CFO van den Boom to step down, Fuhrman appointed
--------------------------------------------------------------------------------

- Net loss of $12.5M in Q3 2022 vs $6.6M a year ago; cash and equivalents $263.2M.
- R&D expenses $10.9M (up from $5.5M); G&A expenses $2.7M (up from $1.2M).
- CFO Esther van den Boom resigns effective Dec 31, 2022; will provide transitional consulting services.
- Alan Fuhrman appointed CFO effective Jan 1, 2023; base salary $440k, target bonus 40%, equity grants.
- SURF301 study ongoing; IND for TYRA-200 expected by year-end 2022.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1863127/000095017022021888/0000950170-22-021888-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1863127/000095017022021888/tyra-20221028.htm
  HTML page:      https://secwatch.observer/filing/0000950170-22-021888

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer